18 résultats avec le mot-clé: 'control immune responses chronic hepatitis c virus infection'
Until recent years, treatment of chronic hepatitis C based on combination therapy of peg-IFN Į and Ribavirin only resulted in approximately 50% of achieving
N/A
Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Forns X, Payette
N/A
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.. Erythropoietic response to anemia in chronic
N/A
Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus
N/A
Hepatitis C virus infection seems to play an important role in the development of chronic liver pathology; 40% of cirrhotic patients had a combined hepatitis B and C virus
N/A
Asian studies suggest the association between HCV infection and an increased risk of carotid- artery plaques and carotid intima-media thickening, independently of classical
N/A
OBJECTIVE: To study the specific impact of treatments for chronic hepatitis C virus (HCV) infection on anger expression and control in adult patients coinfected with HIV
N/A
Hepatitis C virus genotypes and co-infection with GB virus C in patients with anti- HCV-positive chronic liver disease in Jakarta, Indonesia. Int
N/A
Results are expressed as means ± SD percentage HCVcc infection compared to Huh7.5.1 and Huh7.5.1-NTCP cells treated with control peptide (both set at 100%) from three
N/A
2017 Guidelines on testing and diagnosis of hepatitis B and C, and the WHO 2018 Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus
N/A
L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des
N/A
Les malades ont été randomisés en trois bras : bras témoin : IFN pégylé α-2b + ribavirine pendant 48 semaines ; bras TGR : bithérapie de quatre semaines (phase de lead-in), suivie
N/A
Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. Toyoda H, Tada T, Tsuji
N/A
The risk of major cardiovascular events - stroke, ischemic heart disease - is increased in HCV patients, independent of the severity of the liver disease or the common
N/A
Chronic hepatitis C virus infection (HCV) affects approximately 71 million individuals worldwide [1], being a major etiological factor for the development of
N/A
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Molecular biology and inhibitors
N/A
High Efficacy in Patients With Chronic Hepatitis C Virus (HCV) Genotype (GT)1b Infection Treatment With Elbasvir/Grazoprevir for 12 Weeks: An Integrated
N/A
Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology an response
N/A